The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1472
Liletta - A Third Levonorgestrel-Releasing IUD
The full article is available to subscribers Subscriber Login   

The FDA has approved Liletta, an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy for up to 3 years. The fourth IUD to be approved in the US, and the third that releases levonorgestrel, Liletta is comarketed by Actavis and Medicines360, a nonprofit women's health pharmaceutical company. The wholesale cost of Liletta is similar to that of other IUDs (see Table 1), but the manufacturer offers programs that significantly reduce the cost for commercially-insured patients and clinics serving low-income women.1

OTHER IUDs — IUDs provide convenient, long-term contraception and a rapid return to fertility after removal. ParaGard T 380A, a copper-containing IUD, Mirena, which contains 52 mg of levonorgestrel, and Skyla, which contains 13.5 mg ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Liletta - A Third Levonorgestrel-Releasing IUD
Article code: 1472b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian